This clinical trial is for participants with head and neck squamous cell carcinoma who are
scheduled to have their tumor surgically removed. The study involves obtaining baseline
tissue from a clinical biopsy or research biopsy and measurement of circulating tumor cells
before surgery to determine whether AXL protein expression pre-treatment correlates to
clinical outcomes (change in tumor size) after two doses of cetuximab. The importance of this
study is to describe if AXL expression can be used as a biomarker to predict clinical
response to cetuximab (CTX) treatment.
Phase:
Phase 2
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborators:
American Cancer Society, Inc. National Cancer Institute (NCI) National Institute of Dental and Craniofacial Research (NIDCR)